Company
Flindr Therapeutics
First-in-class small molecule oncology precision medicines
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2020
- Legal name
- Flindr Therapeutics
Claim, correct or request removal
Record updated 28 September 2026
About
Flindr develops a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer. We are doing this using our ImmunoGram Drug Discovery Engine, which enables us to discover novel targets in both cancer cells and immune cells.
Funding snapshot
- Latest round
- Series A2024-04-24
Funding rounds
- Series A
- 2024-04-24
Loading relationship preview